Together, the improved efficiency and safety of IL2RG correction via CRISPR-Cas9-based TI approach provides a strong rationale for a clinical trial for treatment of XSCID patients. Here, IL2RG is linked to T-B+ severe combined immunodeficiency due to gamma chain deficiency.